Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Niagen Bioscience (NAGE) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Niagen Bioscience (NAGE) over the last 17 years, with Q3 2025 value amounting to $8.8 million.

  • Niagen Bioscience's Other Operating Expenses rose 2447.47% to $8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.8 million, marking a year-over-year increase of 2396.14%. This contributed to the annual value of $29.5 million for FY2024, which is 1146.46% up from last year.
  • As of Q3 2025, Niagen Bioscience's Other Operating Expenses stood at $8.8 million, which was up 2447.47% from $8.2 million recorded in Q2 2025.
  • Niagen Bioscience's 5-year Other Operating Expenses high stood at $8.8 million for Q3 2025, and its period low was $5.9 million during Q3 2022.
  • In the last 5 years, Niagen Bioscience's Other Operating Expenses had a median value of $7.0 million in 2024 and averaged $7.2 million.
  • Its Other Operating Expenses has fluctuated over the past 5 years, first surged by 4072.41% in 2021, then tumbled by 2839.95% in 2022.
  • Over the past 5 years, Niagen Bioscience's Other Operating Expenses (Quarter) stood at $8.6 million in 2021, then decreased by 28.4% to $6.2 million in 2022, then rose by 5.38% to $6.5 million in 2023, then surged by 33.68% to $8.7 million in 2024, then grew by 0.6% to $8.8 million in 2025.
  • Its last three reported values are $8.8 million in Q3 2025, $8.2 million for Q2 2025, and $8.1 million during Q1 2025.